uab.edu
UAB researchers uncover shared response to dominant commensal bacterial flagellin epitope in Crohn’s patients and healthy infants
The study identifies a specific bacterial protein region (flagellin epitope) that many Crohn’s patients make antibodies to, which could help diagnose disease and predict who may develop complications.
It also connects early-life immune responses to the same epitope, suggesting a possible link between infant immune priming and later Crohn’s risk.
Researchers studying IBD immunology or the microbiome; clinicians and gastroenterologists interested in biomarkers and prognosis for Crohn’s disease; patients and caregivers following advances in diagnostic tests and targeted immunotherapies.
What To Know
Researchers at the University of Alabama at Birmingham report in Gastroenterology that they mapped a dominant B cell epitope within Lachnospiraceae flagellins that drives elevated serum IgG responses in people with Crohn’s disease.
Using a cytometric bead array coated with consensus flagellin peptides, the team measured serum IgG reactivity and found the same dominant epitope is commonly recognized by healthy 1-year-old infants. In a prospective cohort, reactivity to this region at Crohn’s diagnosis was associated with later development of disease complications.
The article highlights a laboratory assay (flagellin peptide cytometric bead array) that could standardize measurement of anti-flagellin IgG and be developed as a diagnostic or prognostic biomarker.
The authors also suggest the identified epitope could be a target for antigen-directed immunotherapies, though the piece does not present clinical trial evidence for treatments. This is a research report describing biomarker discovery and an assay development approach; it summarizes published work without providing patient-care recommendations.
If you’re interested in the original data and methods, read the Gastroenterology paper cited by the UAB news story.
This is a laboratory and cohort research report published in Gastroenterology; findings point to biomarker potential and a possible therapeutic antigen target but do not change current clinical care. Further validation, clinical trials, and regulatory review would be needed before a diagnostic assay or antigen-directed therapy is available.
The UAB news summary describes the published study; consult the original journal article for methods and detailed results.
